Quarterly report pursuant to Section 13 or 15(d)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.7.0.1
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Net loss $ (992,188) $ (2,226,902) $ (4,776,963) $ (3,760,019)  
Cash flows from operations     204,279 (905,660)  
Cash equivalents 0   0   $ 0
Cash in excess of FDIC limits 517,785   517,785    
Allowance for doubtful accounts 500,000   500,000   100,000
Shipping and handling 166,643 111,217 324,002 197,508  
Allowance for customer returns     0 0  
Inventory, noncurrent 5,193,952   5,193,952   6,478,727
Depreciation expense $ 39,322 48,690 $ 86,847 97,715  
Warrants outstanding 2,100,000   2,100,000    
Research and development $ 205,647 341,547 $ 394,363 483,360  
Advertising expense 108,555 67,821 175,455 147,965  
Unrecognized tax benefits 0   0   $ 0
Germany and The Netherlands [Member]          
Inventory, noncurrent 680,515   $ 680,515    
Options and RSU's [Member]          
Stock options outstanding that are antidilutive     16,447,998    
Consumer Products [Member]          
Research and development 55,956 224,266 $ 104,989 366,079  
Specialty Pharmaceuticals [Member]          
Research and development $ 149,691 $ 117,281 $ 289,374 $ 117,281  
Accounts Receivable [Member] | One Customer [Member]          
Concentration risk percentage     41.00%    
Accounts Receivable [Member] | Two Customers [Member]          
Concentration risk percentage         58.00%